Lv312
245 积分 2021-06-12 加入
High time for risk-adapted treatment in mantle cell lymphoma
6天前
已完结
Evolution of mantle cell lymphoma therapy: advancing frontline precision
6天前
已完结
Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase–Targeted Approaches
6天前
已完结
Emerging first-line treatment approaches for mantle cell lymphoma
8天前
已完结
Refining risk stratification for mantle cell lymphoma: integrating novel combination treatments and personalized approaches
8天前
已完结
SOHO State of the Art Updates and Next Questions | Accessing BTK Inhibitors and Other Novel Therapies for Mantle Cell Lymphoma: Are We All Invited to the Party?
8天前
已完结
Refining risk stratification for mantle cell lymphoma: integrating novel combination treatments and personalized approaches
8天前
已完结
Frontline management of mantle cell lymphoma
16天前
已完结
High-risk MCL: recognition and treatment
16天前
已完结
Dismantling relapsed/refractory mantle cell lymphoma
17天前
已完结
皖公网安备34019202002308
